Get started
Author

Паршина Елена Валерьевна

Observed names: E. V. Parshin, E. V. Parshina, E.V. Parshina, Elena Parshina, Elena V. Parshina, Ye. V. Parshina, Ye.V. Parshina, Паршина Е. В.
ORCID: 0000-0001-7033-053X
Observed ORCID: 0000-0001-7033-053X
OpenAlex ID: A5012605216
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 14
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
2024 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13
PDF
Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2
2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13
Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial
2022 · A.N. Boyko, O.V. Boyko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 10
The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis
2019 · A. N. Boyko, K. Z. Bakhtiyarova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 10
Possibilities of daytime anxolytics in the correction of residual neurological manifestations of COVID-19
2021 · E. A. Alexandrova, E. V. Parshina, et al. · Meditsinskiy sovet = Medical Council · 7
PDF
Dynamics of vegetative, insomnia and neuropsychological manifestations during the treatment of post-COVID syndrome
2022 · E. A. Alexandrova, E. V. Parshina, et al. · Meditsinskiy sovet = Medical Council · 5
PDF
Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a
2019 · A. N. Boyko, L. P. Bosenko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 5
A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations
2017 · A. N. Boyko, L. P. Bosenko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 5
Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis
2025 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 4
Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results
2023 · A.N. Boyko, K.Z. Bakhtiyarova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 4
Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
2025 · A. N. Boyko, M. N. Zakharova, et al. · Neurology neuropsychiatry Psychosomatics · 3
PDF
A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Interferon β-1a Formulations for S.C. Administration in Patients with Remitting Multiple Sclerosis: First-Year Results
2018 · A. N. Boiko, L. P. Bosenko, et al. · Neuroscience and Behavioral Physiology · 2
Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial
2026 · Richard J. Nowak, Kimiaki Utsugisawa, et al. · JAMA Neurology · 1
PDF
Болезнь Шегрена с церебральной симптоматикой. Клиническое наблюдение
2020 · Руина Екатерина Андреевна, Боровков Сергей Николаевич, et al. · CyberLeninK (CyberLeninka) · 1
Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
2026 · Alexey N. Boyko, Mariya N. Zakharova, et al. · Annals of Clinical and Experimental Neurology
PDF
Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial
2026 · J. Dawn Abbott, Jocelyne R. Benatar, et al. · Circulation
Rare co-occurrence of multiple sclerosis and Parkinson's disease: a case report
2022 · Ekaterina A. Ruina, Ekaterina A. Aleksandrova, et al. · Annals of Clinical and Experimental Neurology
PDF
Electric stimulation of deep brain structures in the case of Parkinson disease. Algorithm of patients selection, efficiency of treatment
2016 · E.A. Aleksandrova, A.V. Gustov, et al. · Medical Almanac
Пантотенаткиназа-ассоциированная нейродегенерация (болезнь Галлервордена – Шпатца)
2013 · Копишинская Светлана Васильевна, Макушина Светлана Викторовна, et al. · Medical Almanac
Акселерометрическая диагностика мощности тремора при болезни Паркинсона в процессе терапии
2011 · Александрова Екатерина Александровна, Устимкина Мария Алексеевна, et al. · Medical Almanac
Оптимизация помощи больным с болезнью Паркинсона
2010 · Густов Александр Васильевич, Александрова Екатерина Александровна, et al. · cyberleninka.ru
Дивозилимаб снижает риск развития обострений у пациентов с заболеваниями спектра оптиконевромиелита
· Бойко А. Н., Захарова М. Н., et al. · CyberLeninK (CyberLeninka)
Works count: 23
Citation count: 97
H-index: 6
I10-index: 5
Year
Topic
Type